Stay updated with breaking news from Adeera levin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
email article The investigational hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor vadadustat was noninferior to the erythropoiesis-stimulating agent darbepoetin alfa for treating anemia in chronic kidney disease (CKD) patients, a pair of phase III trials found. 2TECT Study of non-dialysis-dependent CKD treatment with vadadustat met the pre-specified noninferiority endpoint for hematologic efficacy compared with darbepoetin alfa, reported Glenn Chertow, MD, MPH, of Stanford University School of Medicine in California, and colleagues. Looking only at ESA-untreated patients, there was an average between-group hemoglobin concentration difference of 0.05 g/dL (95% CI -0.04 to 0.15) maintained from weeks 24 to 36 with vadadustat or darbepoetin alfa treatment. ....